Anupam Rasayan is a custom manufacturer of complex specialty chemicals - it does not sell branded products of its own but instead develops and produces molecules to the exact specifications of multinational customers under decade-long contracts. Founded in 1984 as a conventional chemical maker, it pivoted into custom synthesis in 2006 and has since transformed through a series of acquisitions into a globally diversified platform with manufacturing in India and the United States, serving industries from agriculture to semiconductors. The recurring approach is to control critical raw materials - particularly fluorine-based inputs - and lock in exclusive, long-term supply agreements that make the company a single-source partner for molecules its customers cannot easily replace. # Business segments A single custom-synthesis engine serving five end markets - agrochemicals, pharmaceuticals, performance materials, electronic chemicals, and personal care - strengthened by backward integration into fluorination and a growing manufacturing footprint on two continents. ## 1. Agrochemicals: the foundation that built the platform **The company's largest and most mature vertical, where decade-long relationships with global crop-protection giants generate the steady demand that funds expansion into newer markets.** - **Single-supplier status locks in demand** - for most products in its fluorination series, Anupam is the exclusive supplier out of Asia to originators, meaning customers cannot simply switch to a competitor without risking their own supply chains. - **Contracts span years, not quarters** - the company operates under long-term agreements and Letters of Intent (LOIs) with multinationals like Syngenta, Sumitomo Chemical, and Adama, with products that are integral to customers' manufacturing processes. - **Deliberately shrinking as a share of the whole** - agrochemicals contributed 55% of standalone revenue in FY26, down from 76% in FY22, because management has consciously diversified into pharma and performance materials to reduce dependence on any single end market. - **Built on a 2010 handshake with Syngenta** - the company began supplying agrochemical intermediates to Syngenta in 2010, then added Sumitomo Chemical in 2017, UPL in 2020, and Adama in 2021, layering on new customers one by one over more than a decade. ## 2. Pharmaceuticals: from raw building blocks toward finished medicines **A fast-growing vertical that started with key starting materials for blockbuster drugs and is now being transformed by the acquisition of a finished-dosage manufacturer.** - **Makes the ingredients behind familiar drugs** - the company manufactures intermediates and key starting materials (KSMs) for active pharmaceutical ingredients used in cardiovascular, antidiabetic, and antifungal therapies, including molecules for Atorvastatin, Sitagliptin, and Dapagliflozin. - **Grew roughly sixteen-fold in four years** - standalone pharma revenue rose from ₹21 crores in FY22 to ₹339 crores in FY26, reaching 20% of standalone revenue, driven by commercialising more than 10 molecules over an 18-month period. - **Acquiring a route to the pharmacy shelf** - the pending acquisition of a controlling stake in Bliss GVS Pharma adds forward integration into finished dosage forms - tablets, capsules, injectables, creams - across 50-plus therapeutic segments, with manufacturing accreditations from the U.S. FDA, EU GMP, and WHO. - **Plenty of room to fill existing plants** - Bliss GVS operates six manufacturing facilities with an installed capacity of 4,822 million units but is running at only 30% utilisation, which the company believes can be raised to 60-70% in the near to medium term without building new plants. ## 3. Performance materials and electronic chemicals: the high-tech growth frontier **A portfolio of niche molecules for semiconductors, electric-vehicle batteries, data centres, and defence - the vertical where the company's fluorination edge meets its fastest-growing demand.** - **Fluorine is the common thread** - the polymer sub-segment uses anhydrous hydrogen fluoride across both fluorinated and non-fluorinated chemistries to make specialty monomers and oligomers for aerospace, semiconductor photoresists, and battery salts, all of which depend on the raw materials secured through Tanfac. - **Already supplying the electric-vehicle supply chain** - the company signed an LOI with Elementium Materials for an advanced EV battery electrolyte solvent with projected cumulative sales of $350-450 million over five years, and a separate agreement with E-Lyte and FUCHS for up to 1,500 tonnes per year of Lithium Hexafluorophosphate (LiPF6), a battery chemical Anupam will be among the first to manufacture commercially in India. - **Contracts are measured in decades and hundreds of millions** - a 10-year, $106 million LOI with a South Korean multinational covers a niche chemical for aviation and electronics; a Master Purchase Agreement with a Japanese conglomerate covers multiple molecules for semiconductors and data centres. - **Tripled in four years** - this vertical grew from ₹97 crores in FY22 to ₹305 crores in FY26 on a standalone basis, reaching 18% of standalone revenue, as the company deliberately shifted its mix toward higher-value industrial applications. ## 4. Personal care: the original custom-synthesis relationship **The smallest vertical by revenue, but historically significant - it was the company's first custom-synthesis engagement and remains a steady supplier relationship nearly two decades later.** - **The 2006 contract that changed the company** - Anupam began supplying anti-bacterial products to a German multinational in 2006, marking its pivot from conventional manufacturing into custom synthesis, and it remains a primary supplier of that product to this customer today. - **Ultraviolet protection alongside anti-bacterials** - the vertical now manufactures both anti-bacterial and UV-protection intermediates and ingredients, contributing 7% of standalone revenue in FY26. # Fluorination chemistry and Tanfac: the strategic backbone **Control over fluorine raw materials - secured through a controlling stake in a 50-year-old fluoride manufacturer - is the single most important competitive advantage across every end market the company serves.** - **Fluorine is everywhere in modern chemistry** - over the past 20 years, more than 40% of new products in agrochemicals, pharmaceuticals, and polymers have contained fluorine, making fluorination a critical technology platform that the company has deliberately built its portfolio around. - **Owns its own source of hydrofluoric acid** - Tanfac Industries, acquired in 2022 with a roughly 26% controlling stake, is a leading Indian producer of hydrofluoric acid (HF) and potassium fluoride (KF), with plant capacities of 29,700 MT of HF and 5,000 MT of specialty fluorides, reducing dependence on imports from China. - **The sole Indian manufacturer with uninterrupted access** - Anupam is the only Indian company manufacturing fluorinated molecules with captive access to HF and KF, and it is one of the largest users of potassium fluoride in the country, giving it a supply-chain security that rivals cannot easily replicate. - **A pipeline of 30-plus fluorinated molecules** - the company is developing over 30 identified molecules in fluorination chemistry across polymers, pharmaceuticals, and agrochemicals, many of which will be manufactured in India for the first time, targeting an addressable market of more than $5 billion. # Group structure and partners **Anupam Rasayan operates through a network of subsidiaries and associates that provide vertical integration, geographic reach, and a manufacturing presence on two continents - with each acquisition kept as an independent entity that leverages the group's combined strengths.** - **Tanfac Industries (India)** - a joint venture with Tamil Nadu Industrial Development Corporation, acquired in May 2022, operating a 60-acre manufacturing site in Cuddalore, Tamil Nadu, adjacent to a port; it supplies the fluorinating agents that feed Anupam's downstream value-added products. - **Jayhawk Fine Chemicals (United States)** - acquired in February 2026 for approximately US$150 million through a Luxembourg subsidiary structure, this 80-year-old Kansas-based CDMO operates on roughly 800 acres with less than 10% utilised, generating about two-thirds of its revenue from performance materials for electronics, aerospace, and polymers; it gives Anupam onshore U.S. manufacturing and access to defence and semiconductor markets. - **Bliss GVS Pharma (India, pending)** - being acquired through a definitive agreement for a 43-48% stake plus an open offer, this listed Indian formulations company adds finished-dosage manufacturing with U.S. FDA and EU GMP accreditations, creating a dedicated pharmaceutical platform that will serve as the primary vehicle for future pharma CDMO opportunities. - **Geographic subsidiaries** - wholly owned entities in Japan, Switzerland, the United States, and the UAE, established between 2023 and 2024, serve as local sales and business development offices to support the company's export markets, which contributed 64% of standalone revenue in FY23.